ArriVent BioPharma
AVBP
157 hedge funds and large institutions have $1.6B invested in ArriVent BioPharma in 2026 Q2 according to their latest regulatory filings, with 36 funds opening new positions, 72 increasing their positions, 29 reducing their positions, and 15 closing their positions.
2,372% more call options, than puts
Call options by funds: $33.4M | Put options by funds: $1.35M
148% more repeat investments, than reductions
Existing positions increased: 72 | Existing positions reduced: 29
140% more first-time investments, than exits
New positions opened: 36 | Existing positions closed: 15
120% more funds holding in top 10
Funds holding in top 10: 5 → 11 (+6)
65% more capital invested
Capital invested by funds: $969M → $1.6B (+$632M)
13% more funds holding
Funds holding: 139 → 157 (+18)
3.77% more ownership
Funds ownership: 95.22% → 98.99% (+3.8%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VC
Vivo Capital
Palo Alto,
California
|
+$23.5M |
| 2 |
BlackRock
New York
|
+$21.3M |
| 3 |
LGM
Logos Global Management
San Francisco,
California
|
+$19.2M |
| 4 |
D.E. Shaw & Co
New York
|
+$14.9M |
| 5 |
FCMV
Foresite Capital Management VI
Larkspur,
California
|
+$8.89M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NHAS
Novo Holdings A/S
Hellerup,
Denmark
|
-$13M |
| 2 |
F1I
Fund 1 Investments
Rincon,
Puerto Rico
|
-$11.5M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
-$7M |
| 4 |
Point72 Asset Management
Stamford,
Connecticut
|
-$5.35M |
| 5 |
ACM
ADAR1 Capital Management
Austin,
Texas
|
-$3.27M |
AVBP Hedge Fund Activity: Q2 2026 in Review
157 institutional investors reported a position in ArriVent BioPharma (AVBP) for Q2 2026, worth a combined $1.6B — up 65% from $969M a quarter earlier.
Buyers outnumbered sellers: 36 funds opened new AVBP positions and 15 closed out — a net gain of 21 holders — while 72 added to existing stakes and 29 trimmed.
The largest buyer was Vivo Capital, adding an estimated $23.5M. The largest seller was Novo Holdings A/S, cutting an estimated $13M.
- 157 institutional investors held ArriVent BioPharma (AVBP) as of Q2 2026, up from 139 in Q1 2026.
- Funds reported $1.6B of ArriVent BioPharma stock for Q2 2026, up 65% quarter-over-quarter.
- 36 funds opened new ArriVent BioPharma positions in Q2 2026 and 15 closed out, a net change of +21 holders.
- The largest ArriVent BioPharma buyer in Q2 2026 was Vivo Capital, an estimated $23.5M added.
- The largest ArriVent BioPharma seller in Q2 2026 was Novo Holdings A/S, an estimated $13M sold.
Based on aggregated 13F filings for Q2 2026.